Compare BIO-TECHNE Corp (TECH) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Sprott Uranium Miners ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Sprott Uranium Miners ETF trades at $55.37. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Sprott Uranium Miners ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| TECH | URNM | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $72.29 | $83.99 |
52-Week Low | $43.31 | $44.14 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
URNM trades at $54.53, up 2.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF, focused on uranium miners, benefits from growing nuclear energy demand driven by AI power needs and government support, as highlighted in recent news. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook for URNM is positive due to structural tailwinds in nuclear energy, but risks include high volatility from commodity prices and concentrated miner exposure. Investors should weigh the bullish technical setup against the lack of transparent valuation metrics and potential sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
